Wet Age-Related Macular Degeneration (Wet AMD) Market Size to Reach US$ 16,864.9 Million by 2034, Impelled by Advancements in Early Detection

Wet Age-Related Macular Degeneration (Wet AMD) Market Outlook 2024-2034:

The wet age-related macular degeneration (Wet AMD) market size reached a value of US$ 8,997.9 Million in 2023. Looking forward, the market is expected to reach US$ 16,864.9 Million by 2034, exhibiting a growth rate (CAGR) of 5.9% during 2024-2034. The market is driven by the inflating utilization of gene therapy for the treatment of wet AMD. The goal is to provide a one-time therapy that helps the eye make its anti-vascular endothelial growth factor (anti-VEGF) treatment.

Advances in Early Detection and Diagnostic Technologies: Driving the Wet Age-Related Macular Degeneration (Wet AMD) Market 

Advances in early detection and diagnostic technologies are transforming the wet age-related macular degeneration (Wet AMD) market, offering hope for more effective and timely interventions for this prevalent cause of vision loss in older adults.  Moreover, recent innovations in imaging technologies, such as optical coherence tomography (OCT) and fundus photography, have revolutionized the diagnostic landscape for Wet AMD. OCT provides high-resolution, cross-sectional images of the retina, enabling clinicians to detect subtle structural changes long before significant vision loss occurs. Besides this, biomarker discovery has opened new avenues for early detection. Researchers are increasingly identifying biomarkers in blood and ocular fluid that correlate with Wet AMD onset and progression. Biomarker-based diagnostics could enable non-invasive, routine screening for individuals at high risk, potentially preventing severe vision impairment by initiating treatment earlier. Furthermore, telemedicine has gained popularity in reaching patients in remote or underserved locations, providing accessible diagnostic services using mobile retinal imaging devices. Combined with AI, these devices enable early Wet AMD detection outside of traditional clinical settings, expanding the reach of preventive care. Moreover, the continuous advancements in diagnostic technologies for Wet AMD are not only improving patient outcomes but are also driving the market. These innovations reduce the economic burden on healthcare systems by enabling earlier intervention, improving patient access, and ultimately, preserving sight for those affected by this progressive condition.

Development of Novel Therapies and Pharmacological Treatments: Contributing to Market Expansion

The development of novel therapies and pharmacological treatments is revolutionizing the management of wet age-related macular degeneration (Wet AMD), thereby expanding the market growth. Traditional treatments, mainly anti-VEGF therapies like ranibizumab and aflibercept, have shown effectiveness in slowing disease progression by targeting the abnormal blood vessels that characterize Wet AMD. However, these treatments typically require frequent intraocular injections, presenting challenges in patient adherence and clinical burden. In line with this, the pharmaceutical industry is investing heavily in next-generation therapies that improve treatment efficacy and convenience. For example, extended-release drug delivery systems, such as the Port Delivery System (PDS) with ranibizumab, are being developed to reduce injection frequency while maintaining therapeutic outcomes. By releasing the drug gradually, these systems allow for fewer clinic visits, thereby improving patient compliance and quality of life. Moreover, the emerging application of gene therapy approaches, including adeno-associated viral (AAV) vectors delivering anti-VEGF genes, is also propelling the market growth. These techniques aim to provide sustained therapeutic effects from a single administration, potentially reducing or eliminating the need for repeated treatments. Similarly, stem cell-based therapies are being explored to regenerate retinal tissue and restore vision, holding promise for patients with advanced disease stages. Emerging therapies targeting inflammation and complement system dysregulation, both of which are implicated in Wet AMD pathogenesis, offer new treatment pathways. Complement inhibitors, such as pegcetacoplan, are under investigation to slow disease progression by addressing inflammatory components, which could benefit patients unresponsive to anti-VEGF treatments. These innovations are driving the Wet AMD market by expanding treatment options, enhancing patient outcomes, and meeting the high demand for effective, less invasive solutions.

Regional Analysis:

The major markets for wet age-related macular degeneration (Wet AMD) include the United States, Germany, France, the United Kingdom, Italy, Spain, and Japan. According to projections by IMARC, the United States has the largest patient pool for wet age-related macular degeneration (Wet AMD) while also representing the biggest market for its treatment. This can be attributed to numerous technological advancements in diagnostics, such as OCT that enable earlier and more accurate diagnosis of the condition, allowing for timely intervention.

Moreover, the aging population and improvements in treatment choices are the main drivers of the Wet AMD market in the United States. As the population ages, the prevalence of Wet AMD rises, creating a substantial demand for effective treatments that can preserve vision and quality of life in older adults. This demographic shift intensifies the need for innovative therapies, especially as more patients seek solutions with fewer side effects and better long-term outcomes.

Additionally, the pipeline of potential medications and treatment modalities, such as complement inhibitors, gene therapy, and extended-release anti-VEGF medicines, has also been fueled by big pharmaceutical companies' investment in R&D. This, in turn, is bolstering the market growth in the U.S​.

Key information covered in the report.

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

 Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the wet age-related macular degeneration (Wet AMD) market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the wet age-related macular degeneration (Wet AMD) market
• Reimbursement scenario in the market
• In-market and pipeline drugs
   

Competitive Landscape:

This report offers a comprehensive analysis of current wet age-related macular degeneration (Wet AMD) marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

 Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. Across the six major continents and 100+ countries, we work alongside our business partners as one team with a common ambition to achieve unparallelled results, gain a competitive edge, and transform industries. IMARC Group excels in understanding its clients’ business priorities and delivering tailored solutions that drive meaningful outcomes. Our client base spans over 3,000 organizations in the private, public, and social sectors, ranging from high-growth startups to Fortune 500 companies.

Contact US

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Phone Number: - +1 631 791 1145, +91-120-433-0800